Image

A Dose-escalation Clinical Study of Intraoperative Photodynamic Therapy of Glioblastoma

Recruiting
18 - 69 years of age
Both
Phase 1/2

Powered by AI

Overview

The primary objective of this clinical trial is to determine the safety and tolerability of two doses of light in intraoperative PDT added to standard of care; temozolomide-based chemotherapy in male and female patients aged 18 to 69 with newly diagnosed glioblastoma.

This treatment will be carried out in addition to the maximal surgical resection. Data collected during this trial will be used to design the upcoming pivotal study .

The study will utilize an independent Data and Safety Monitoring Board (iDSMB) that will review safety data to allow dose escalation.

Description

This study is a non randomized, open label, single center , phase 1/2 trial with a sequential enrollment in a 3+3 dose escalation design to establish the maximal tolerated dose of light (MTD).

The dose of light will be escalated in successive cohorts of patients until at least 1 patient experiences a dose-limiting toxicity (DLT).

A DLT is defined as any grade ≥ 3 Adverse Event (AE), or any relevant grade 2 AE of Central Nervous System or any Serious Adverse Events (SAEs) possibly, probably or definitively related to the intraoperative PDT (i.e., 5-aminolevulinic acid hydrochloride (5-ALA HCl) administration + brain cavity illumination), for which the onset date is within 28 days after the procedure, and where conservative therapy fails and surgical is required, according to the NCI Common Terminology Criteria for Adverse Events (CTCAE) version 5.0.

After dose escalation patient will be followed in the standard of care until visit at 6 months to evaluate the progression free survival.

Eligibility

Inclusion criteria

  1. Males or females must be between 18, or legal age of consent, and 69 years of age (inclusive) at the time of signing informed consent.
  2. Signed informed consent which includes compliance with requirements and restrictions listed in the informed consent.
  3. Newly diagnosed GBM (grade IV malignant high-grade glioma), presumed on the basis of clinical and MRI criteria (intra-axial brain tumor with peripheral rim contrast enhancement)
  4. Karnofsky Performance Scale ≥ 60
  5. Eligible for surgery
  6. Amenable to maximal tumor resection based on MRI.
  7. Planned to receive SOC (i.e., Stupp Protocol) treatment after surgery.
  8. Ability to take oral medications.

Exclusion criteria

  1. Patients with radiographic tumors of/or involving unresectable midline, basal ganglia, or brain stem as assessed by MRI.
  2. Patient with Lynch syndrome
  3. Patient with Li-Fraumeni syndrome
  4. Debilitating cardiopulmonary disease
  5. Any history of cancer
  6. Clinically significant abnormal ECG results, including a corrected QT interval QtCf > 480 ms.
  7. Creatinine clearance < 60 mL/min
  8. Severe hepatic impairment (bilirubin > 1.5 x the upper limit of normal [ULN] or alkaline phosphatase or transaminases (AST, ALT) > 2.5 x ULN)
  9. Known allergic reactions to silicone.
  10. Known allergic reactions or hypersensitivity to egg, soya, or peanut proteins.
  11. Febrile illness
  12. Contraindication to 5-ALA HCl administration, including:
    1. Porphyria
    2. Taking photosensitizing drugs 24 hours before administration of Pentalafen®
    3. Inability to suspend a long-term hepatotoxic treatment for 24 hours after 5-ALA HCl intake.
  13. Contraindication to MRI examination (e.g., pacemaker or metallic foreign body)
  14. Treatment with another investigational drug or intervention within 30 days prior to or during the entire study
  15. Predictable non-compliance with the rules for preventing the transient risk of skin photosensitization.
  16. Clinical follow up not possible for psychological, family, social, or geographic reasons.
  17. Legal incapacity
  18. Pregnancy or lactation Women of childbearing potential (WOCBP) and males with WOCBP partners not willing to use an effective contraceptive method from inclusion until end of study

Study details

Primary Glioblastoma

NCT05736406

Hemerion Therapeutics

1 June 2024

Step 1 Get in touch with the nearest study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

FAQs

Learn more about clinical trials

What is a clinical trial?

A clinical trial is a study designed to test specific interventions or treatments' effectiveness and safety, paving the way for new, innovative healthcare solutions.

Why should I take part in a clinical trial?

Participating in a clinical trial provides early access to potentially effective treatments and directly contributes to the healthcare advancements that benefit us all.

How long does a clinical trial take place?

The duration of clinical trials varies. Some trials last weeks, some years, depending on the phase and intention of the trial.

Do I get compensated for taking part in clinical trials?

Compensation varies per trial. Some offer payment or reimbursement for time and travel, while others may not.

How safe are clinical trials?

Clinical trials follow strict ethical guidelines and protocols to safeguard participants' health. They are closely monitored and safety reviewed regularly.
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.